Winrevair
Payments companies reported to CMS as associated with Winrevair. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Winrevair, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Winrevair
These are the largest totals companies reported as associated with Winrevair. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Ioana Preston | Burlington, MA | Critical Care Medicine (Internal Medicine) | $109,649.52 |
| Ronald Oudiz | Torrance, CA | Cardiovascular Disease | $87,997.82 |
| Richard Channick | Boston, MA | Critical Care Medicine (Internal Medicine) | $86,378.67 |
| Rajan Saggar | Los Angeles, CA | Pulmonary Disease | $82,675.34 |
| John Ryan | Salt Lake City, UT | Cardiovascular Disease | $82,489.62 |
| Hyong Kim | La Jolla, CA | Internal Medicine | $80,874.04 |
| John Mcconnell | Louisville, KY | Pulmonary Disease | $64,580.07 |
| Raj Parikh | Hartford, CT | Pulmonary Disease | $62,042.31 |
| Lana Melendres Groves | Albuquerque, NM | Pulmonary Disease | $61,983.33 |
| Aaron Miller | Columbia, MO | Pulmonary Disease | $60,516.54 |
Prescribed Winrevair?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.